Bepranemab, Placebo matching and without active substance, Neuraceq 300 MBq/mL solution for injection, (18F) GTP1
AH0003
Phase 2 small_molecule active
Quick answer
Bepranemab, Placebo matching and without active substance, Neuraceq 300 MBq/mL solution for injection, (18F) GTP1 for Alzheimer’s Disease is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Alzheimer’s Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active